Caro, JJ, Salas, M, Ward, A, Goss, G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001; 91: 2214–2221.3.0.CO;2-P>CrossRefGoogle Scholar

Ludwig, H, Van Belle, S, Barrett-Lee, P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. European Journal of Cancer. 2004; 40:2293–2306.CrossRefGoogle ScholarPubMed

Tonia, T, Mettler, A, Robert, N, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database of Systematic Reviews. 2012; 12:CD003407.Google ScholarPubMed

Knight, K, Wade, S, Balducci, L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. The American Journal of Medicine. 2004; 116 Suppl 7A:11S–26S.Google Scholar

Groopman, JE, Itri, LM. Chemotherapy-induced anemia in adults: incidence and treatment. Journal of the National Cancer Institute. 1999; 91:1616–1634.CrossRefGoogle ScholarPubMed

Spivak, JL. The anaemia of cancer: death by a thousand cuts. Nature Reviews Cancer. 2005; 5:543–555.Google Scholar

Maccio, A, Madeddu, C, Massa, D, et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood. 2005; 106:362–367.Google Scholar

Hohaus, S, Massini, G, Giachelia, M, et al. Anemia in Hodgkin’s lymphoma: the role of interleukin-6 and hepcidin. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2010; 28:2538–2543.Google Scholar

Tisi, MC, Bozzoli, V, Giachelia, M, et al. Anemia in diffuse large B cell non-Hodgkin Lymphoma: the role of IL-6, hepcidin and erythropoietin. Leukemia & Lymphoma. 2013.CrossRefGoogle Scholar

Sharma, S, Nemeth, E, Chen, YH, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2008; 14:3262–3267.Google Scholar

Santos, FP, Alvarado, Y, Kantarjian, H, et al. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer. 2011; 117:982–991.Google Scholar

Van Glabbeke, M, Verweij, J, Casali, PG, et al. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). European Journal of Cancer. 2006; 42:2277–2285.Google Scholar

Funakoshi, T, Latif, A, Galsky, MD. Risk of hematologic toxicities in cancer patients treated with sunitinib: A systematic review and meta-analysis. Cancer Treatment Reviews. 2013; 39:818–830.Google Scholar

Goodnough, LT, Nemeth, E, Ganz, T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood. 2010; 116:4754–4761.Google Scholar

Wright, JR, Ung, YC, Julian, JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2007; 25:1027–1032.Google Scholar

Smith, RE Jr., Aapro, MS, Ludwig, H, et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2008; 26:1040–1050.Google Scholar

Khorana, AA, Francis, CW, Blumberg, N, et al. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Archives of Internal Medicine. 2008; 168:2377–2381.Google Scholar

Grant, MD, Piper, M, Bohlius, J, et al. Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment: Comparative Effectiveness Update. AHRQ Comparative Effectiveness Reviews. Rockville (MD); 2013.Google Scholar

FDA Briefing Document Oncologic Drugs Advisory Committee. 2008 [accessed May 26, 2017]. Available from: www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4345b2-01-FDA.pdf.Google Scholar

Bohlius, J, Schmidlin, K, Brillant, C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009; 373:1532–1542.Google Scholar

Pfeffer, MA, Burdmann, EA, Chen, CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. The New England Journal of Medicine. 2009; 361:2019–2032.Google Scholar

Henke, M, Laszig, R, Rube, C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003; 362:1255–1260.Google Scholar

Leyland-Jones, B, Semiglazov, V, Pawlicki, M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005; 23:5960–5972.Google Scholar

Untch, M, von Minckwitz, G, Konecny, GE, et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer–outcome on prognosis. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO. 2011; 22:1999–2006.CrossRefGoogle ScholarPubMed

Leyland-Jones, B, Bondarenko, I, Nemsadze, G, et al. A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2016; 34:1197–1207.CrossRefGoogle ScholarPubMed

McKinney, M, Arcasoy, MO. Erythropoietin for oncology supportive care. Experimental Cell Research. 2011; 317:1246–1254.CrossRefGoogle ScholarPubMed

Rizzo, JD, Brouwers, M, Hurley, P, et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010; 116:4045–4059.Google Scholar

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Cancer- and Chemotherapy-Induced Anemia, updated November 16, 2016 [accessed May 26, 2017]. Version 2.2017. Available from: www.nccn.org/professionals/physician_gls/pdf/anemia.pdf.Google Scholar

Engert, A, Josting, A, Haverkamp, H, et al. Epoetin alfa in patients with advanced-stage Hodgkin’s lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2010; 28:2239–2245.Google Scholar

Moebus, V, Jackisch, C, Schneeweiss, A, et al. Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. Journal of the National Cancer Institute. 2013; 105:1018–1026.Google Scholar

Schrijvers, D, De Samblanx, H, Roila, F, E.G.W. Group. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO. 2010; 21(Suppl)5:v244–v247.Google Scholar

Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy: National Institute for Health and Clinical Excellence technology appraisal guidance TA323; 2014 [accessed May 26, 2017]. Available from: www.nice.org.uk/guidance/ta323.Google Scholar